This research study wants to develop advanced imaging methods to more accurately characterize prostate cancer or solid tumor aggressiveness. This observational study involves \[18F\]DCFPyL positron emission tomography and magnetic resonance imaging (PET/MRI)
This is an observational imaging study to evaluate the value of multimodal \[18F\]DCFPyL positron emission tomography and magnetic resonance imaging (PET/MRI) for solid tumor characterization and disease staging. This research study involves: * Screening visit, and 1-3 study Multimodal \[18F\]DCFPyL PET/MRI visits * Two cohorts of participants will be enrolled in this study: primary prostate cancer patients and patients with known or suspected solid tumors (hepatocellular carcinoma, glioma, clear cell renal carcinoma) * It is expected that about 135 people will take part in this research study * The PET dye used in this study is called \[18F\]DCFPyL. \[18F\]DCFPyL is approved by the U.S. Food and Drug administration (FDA). * The PET/MRI scanner was approved by the U.S. FDA.
Study Type
OBSERVATIONAL
Enrollment
50
will either be administered by intravenous injection by bolus by a qualified nuclear medicine technician at the Martinos Center, or will be administered as part of a clinical PET/CT examination
PET/MRI Scan with \[18F\]DCFPyL as directed by protocol
Massachusetts General Hospital
Boston, Massachusetts, United States
Diagnostic value of multimodal imaging in primary prostate cancer patients
First tumor aggressiveness will be identified by binarizing the Gleason grade scores (GG ≥ 3+4). Binarized tumor aggressiveness obtained from the machine learning techniques will be then compared to the gold-standard, histopathology.
Time frame: 3 Days
Scan-rescan repeatability
Repeated measures analysis of covariance (ANCOVA) to evaluate statistical significance using a multilevel analysis to accommodate the nested structure of the data (longitudinal correlated data). Wilcoxon signed rank test will be used to assess for differences in each imaging parameter across visits. Spearman rank correlation will be used to test the correlation between \[18F\]-DCFPyL binding as measured by standardized uptake values (SUV) and Ktrans or SUV and cerebral blood flow (CBF). The false discovery rate will be used to adjust for multiple testing.
Time frame: 6 months
This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.